Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Janet Woodcock Retires From US FDA: ‘I’m Trying To Tie Up All The Loose Ends’

Jan 27 2024

• By Derrick Gingery

Janet Woodcock — • Source: FDA

Related Content

‘The Largest Reorganization In FDA’s History’: ORA Overhaul Better Thought Of As Agency-Wide Reorg

Jan 21 2024

Immortalizing Janet Woodcock

Jan 23 2024

The Two Towers: US FDA's HQ Expansion Plans Include Office High-Rises, New Conference Center

Sep 18 2018

Califf Outlines Clinical Trial Reform Message, Which Could Travel With Him To Commissioner’s Office

Nov 23 2021

US FDA Could Have Avoided Clinical Data Waste With Authority Over All COVID-19 Trials

Jun 27 2023

With Woodcock’s Retirement, US FDA Loses A Renaissance Woman

Nov 17 2023

Woodcock Touts Baby Steps Toward Global Manufacturing Quality Dossier

Oct 19 2023

She Didn’t Need To Be Commissioner: Janet Woodcock’s Transformative Legacy

Dec 02 2021

Peter Marks’ Fears May Come True: White House Wants More In-Person Work

Aug 09 2023

CDER’s Woodcock Retiring? Rumors Never Go On Furlough

Oct 14 2013

Related Companies

Sarepta Therapeutics, Inc.

Additional Topics

United States FDA Leadership Regulation Clinical Trials BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window